BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
TYRA-300 increased the length of the appendicular skeleton in the FGFR3 mutated mice: the femur by 3.70% compared to the vehicle, the tibia by 3.75%, the humerus by 3.22%, and the ulna by 5.03%.BofA Securities has upgraded Tyra Biosciences (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines.
美國銀行證券已將泰拉生物科技（納斯達克：TYRA）評級上調，這是一家專注於開發下一代精準藥物的臨床階段生物技術公司。
The company's initial focus is on improving small molecule drug discovery and development in targeted oncology and genetically defined conditions.
公司最初的重點是改善靶向腫瘤治療和基因定義條件中的小分子藥物發現和開發。
The company has a pipeline of four preclinical candidates. In July, Tyra Biosciences announced preclinical proof-of-concept results with TYRA-300 in hypochondroplasia (HCH), the most common form of dwarfism.
該公司擁有四個臨床前候選藥物。7月，泰拉生物科技宣佈TYRA-300在成骨發育不全（HCH）中的臨床前概念驗證結果，成骨發育不全是最常見的侏儒症形式。
TYRA-300 increased the length of the appendicular skeleton in the FGFR3 mutated mice: the femur by 3.70% compared to the vehicle, the tibia by 3.75%, the humerus by 3.22%, and the ulna by 5.03%.
TYRA-300相對於對照組，增加了FGFR3突變小鼠四肢骨骼的長度：股骨增加了3.70％，脛骨增加了3.75％，肱骨增加了3.22％，尺骨增加了5.03％。
TYRA-300 also increased the size of the foramen magnum by 5.88% (p<0.05) in mice. TYRA-300 demonstrated binding against the FGFR3 N540K altered protein and isoform selectivity for FGFR3 over other isoforms.
TYRA-300還使小鼠枕骨孔的尺寸增加了5.88％（p
BofA has upgraded Tyra Biosciences from Neutral to Buy with a price target of $31, up from $22, ahead of the upcoming presentation of the phase 1/2 SURF-301 of TYRA-300 for urothelial carcinoma/ solid tumors at the ENA Meeting next week.
美國銀行已將泰拉生物科技的評級從中立調升至買入，並將其目標股價從22美元提高至31美元，這在泰拉生物科技即將在下週的ENA會議上展示TYRA-300用於膀胱癌/實體腫瘤的1/2期SURF-301之前。
The analyst suggests that while Johnson & Johnson's (NYSE:JNJ) erdafitinib may have established a high efficacy benchmark, its poor tolerability has significantly limited its use.
分析師指出，儘管強生（紐交所：JNJ）的厄達尼替尼可能已樹立了高療效標杆，但其較差的耐受性極大限制了其使用。
"To that end, we think the bar for success for '300 is safety vs. efficacy," BofA analyst writes.
「因此，我們認爲‘300的成功標準是安全性與療效之間的評判基準，」美國銀行分析師寫道。
The updated model reflects greater potential uptake of an FGF3R-inhibitor with a differentiated safety profile while increasing the likelihood of success (LoS) risk adjustment to 35% from 15% prior in mUC.
更新後的模型反映出FGF3R抑制劑具有不同安全性草案的更大潛在吸收能力，並將成功的可能性（LoS）風險調整從之前的15%提高到35%。
The analyst projects 2030 adjusted sales for metastatic urothelial carcinoma to reach $175 million, up from a previous estimate of $35 million, compared to the consensus of $182 million.
分析師預測，到2030年，轉移性膀胱癌的調整銷售額將達到17500萬美元，較之前的3500萬美元的預估提高，相比共識的18200萬美元。
The analyst highlights that Tyra Biosciences stock had a strong year (YTD +89% vs. +10% NBI)
分析師強調，泰勒生物科技股票今年表現強勁（截至目前+89%，而NBI+10%）。
Price Action: TYRA stock is up 3.77% at $26.96 at last check Friday.
股價走勢：TYRA股價上漲3.77%，報26.96美元，上週五最後一次查詢。
Photo via Shutterstock
圖片來自shutterstock。
- Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug.
- 歐洲藥品監管機構的諮詢小組建議批准諾和製藥在澳大利亞獲批的血友病藥物。
譯文內容由第三人軟體翻譯。
